Quoin Pharmaceuticals Partners with Squirro to Enhance AI Capabilities in Biotechnology

Swiss Rockets AG Partners with Squirro AG to Revolutionize AI in Biotechnology

Swiss Rockets AG, a biotechnology incubator and accelerator based in Basel, has announced a strategic partnership with Squirro AG, a leading Swiss enterprise AI company, to enhance its artificial intelligence (AI) capabilities. This collaboration, unveiled on October 23, 2025, focuses on integrating Squirro's Generative AI Platform into the digital knowledge ecosystem of Swiss Rockets. The main objective of this initiative is to accelerate innovation within Swiss Rockets’ biotech portfolio, optimize research processes, and improve decision-making. The partnership promises to create a unified intelligence layer through the implementation of Squirro's AI and Knowledge Graph technologies, aiming to generate an AI-powered assistant capable of summarizing and connecting information from internal documents, research archives, and public sources.

The collaboration marks a significant step towards transforming Swiss Rockets into a fully AI-empowered entity. Sergey Kravchenko, Executive Chairman of Squirro, underlines the potential of AI to enable organizations to achieve more with fewer resources. Meanwhile, Dr. Vladimir Cmiljanovic, Founder and CEO of Swiss Rockets, emphasizes the importance of this partnership in enhancing knowledge management and decision-making across the organization. The rollout of the Swiss Rockets AI Assistant will serve as the first phase of this transformative journey, with subsequent use cases planned to focus on research intelligence and knowledge management. This initiative reflects a broader trend within the biotechnology sector to leverage AI for improved efficiency and effectiveness.

In addition to the operational enhancements, both companies are committed to ensuring that their AI practices align with security and regulatory standards. The systems will be hosted in Swiss Rockets' ISO 27001-certified Swiss cloud environment, ensuring compliance with GDPR, HIPAA, and the EU AI Act. This focus on secure and responsible AI deployment not only enhances the credibility of the partnership but also sets a benchmark for innovation in the life sciences sector. As the collaboration unfolds, it is expected to significantly impact how biotech organizations utilize AI to drive research and development.

In a parallel development, INOVIO, a biotechnology firm specializing in DNA medicines for treating HPV-associated diseases, cancer, and infectious diseases, is preparing to participate in the upcoming Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025. This event will facilitate one-on-one meetings between INOVIO’s management team and investors, underscoring the company's commitment to fostering investor relationships and promoting its pioneering work in the biotechnology field.

As the industry continues to evolve, collaborations like the one between Swiss Rockets and Squirro highlight the growing importance of AI in enhancing research capabilities and operational efficiencies within the biotech sector.